Pfizer announced that the Centers for Medicare and Medicaid Services (CMS) will cover the cost of the company’s biosimilar Inflectra (infliximab-dyyb) for Medicare enrollees as a Part B-covered drug. Inflectra was approved by the FDA in April 2016 as a biosimilar to Janssen Biotech’s Remicade (infliximab) for reducing signs and symptoms in patients with rheumatoid arthritis, adult and pediatric Crohn’s disease, adult ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and chronic severe plaque psoriasis.
The CMS reimbursement price, which took effect January 1, 2017, is a 15% discount to the Wholesale Acquisition Cost (WAC) of Remicade. The WAC does not include discounts to payers, providers, distributors, and other purchasing organizations.
Inflectra is the first biosimilar monoclonal antibody, and the second biosimilar, to become available in the United States. The FDA’s approval of Inflectra as a biosimilar to Remicade did not include interchangeability with the reference drug; pharmacists cannot substitute Inflectra for Remicade without a physician’s instructions.
Pfizer announced the launch of the Pfizer enCompass program, a reimbursement service and patient support program offering coding and reimbursement support for providers, co-pay assistance to eligible patients who have commercial insurance that covers Inflectra, and financial assistance for eligible uninsured and underinsured patients.
Pfizer also announced the availability of pricing for 340B hospitals, a drug pricing program for eligible healthcare organizations that serve as safety net providers, including Medicare/Medicaid Disproportionate Share Hospitals, children’s hospitals, Ryan White clinics, and State AIDS Drug Assistance Programs.
Inflectra began shipping to wholesalers in late November 2016, and can now be ordered from wholesalers across the country.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Unlocking Biosimilar Potential in Specialty Pharmacies With Legislative Support, Formulary Changes
April 24th 2025Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming unique challenges in specialty pharmacies and driving the growth of biosimilar adoption, which has significant cost saving potential in the next decade.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.